Timeline of events and laboratory investigations after CART therapy
| Days after COVID infection . | B-cell or lymphocyte count . | Length of hospital stay with COVID pneumonitis (d) . | Treatment received for COVID pneumonitis . | SARS-CoV-2 IgG status via PCR assay . | T-cell response assay . |
|---|---|---|---|---|---|
| –200 | Complete B-cell aplasia, measured at days –200, –46, +17, +52, and +108 from first admission with COVID pneumonitis. Lymphocyte count <1 × 109/L at all of these time points | ||||
| 0 | 10 | Remdesivir (5 d) plus dexamethasone (10 d) | PCR-positive | ||
| 17 | 19 | Remdesivir (5 d) plus dexamethasone (10 d) plus tocilizumab (1 dose) plus nitazoxanide | PCR-positive | ||
| 70 | 16 | Remdesivir (5 d) plus meropenem (Klebsiella in bronchoalveolar lavage) plus amphotericin B/voriconazole (increased galactomannan) | PCR-positive | ||
| 110 | PCR-negative in stool and nasopharyngeal aspirate | ||||
| 128 | Persistent B-cell aplasia, lymphocyte count 1.38 × 109/L | SARS-CoV-2 IgG negative in serum | Good proliferative response to spike, nucleocapsid, and membrane proteins |
| Days after COVID infection . | B-cell or lymphocyte count . | Length of hospital stay with COVID pneumonitis (d) . | Treatment received for COVID pneumonitis . | SARS-CoV-2 IgG status via PCR assay . | T-cell response assay . |
|---|---|---|---|---|---|
| –200 | Complete B-cell aplasia, measured at days –200, –46, +17, +52, and +108 from first admission with COVID pneumonitis. Lymphocyte count <1 × 109/L at all of these time points | ||||
| 0 | 10 | Remdesivir (5 d) plus dexamethasone (10 d) | PCR-positive | ||
| 17 | 19 | Remdesivir (5 d) plus dexamethasone (10 d) plus tocilizumab (1 dose) plus nitazoxanide | PCR-positive | ||
| 70 | 16 | Remdesivir (5 d) plus meropenem (Klebsiella in bronchoalveolar lavage) plus amphotericin B/voriconazole (increased galactomannan) | PCR-positive | ||
| 110 | PCR-negative in stool and nasopharyngeal aspirate | ||||
| 128 | Persistent B-cell aplasia, lymphocyte count 1.38 × 109/L | SARS-CoV-2 IgG negative in serum | Good proliferative response to spike, nucleocapsid, and membrane proteins |
PCR, polymerase chain reaction.